Reference/Tripeptide

KPV

Anti-Inflammatory Tripeptide · Alpha-MSH Fragment

Animal in vivo

research use only

KPV is a potent anti-inflammatory tripeptide derived from the C-terminal of alpha-MSH. It exhibits remarkable anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH, making it ideal for inflammation management.

Systemic anti-inflammatory effectsNo pigmentation/tanning effectsImmune modulation without immunosuppressionPotential for autoimmune conditions

5 citations·0 with human data·Updated 10 Aug 2026

Overview

Enters cells and inhibits inflammatory pathways at the nuclear level, particularly NF-κB signaling. Reduces pro-inflammatory cytokines (TNF-α, IL-6) without causing immunosuppression like steroids.

Evidence profilederived from 5 references

Animal in vivo

Strongest design among the references on this page. Grade and effect size are separate facts and are never merged into one score.

Research indications

What the compound has been studied for, grouped by body system. Effect size is the reported magnitude where it was measured — not a recommendation.

Inflammation3

Systemic Inflammation

Reduces TNF-α and IL-6 through NF-κB pathway inhibition.

Large

Autoimmune Modulation

May help balance overactive immune responses in autoimmune conditions.

Moderate

Joint Inflammation

Potential benefits for inflammatory arthritis through cytokine reduction.

Moderate

Gut Health3

IBD Support

Demonstrated benefit in Crohn's disease and ulcerative colitis models.

Moderate

Intestinal Barrier Repair

Helps restore intestinal barrier function.

Moderate

Microbiome Balance

Selective antimicrobial activity preserves beneficial gut bacteria.

Small

Skin Health2

Psoriasis/Dermatitis

Topical KPV reduced psoriatic markers by 60% and improved skin barrier function.

Moderate

Skin Inflammation

Reduces inflammatory skin conditions without systemic effects.

Moderate

A large effect in a weak study and a small effect in a strong one are different things. Effect size is never evidence of use in people.

Quick factsreference only

Class: Tripeptide
Chain length: 3 residues
Half-life: ~1.5 h
Typical dose: 200-500 mcg per injection
Frequency: 1-2 times daily (once for maintenance, twice for active inflammation)
Cycle length: 4-8 weeks
Storage: Lyophilized: Room temperature. Reconstituted: 2-8°C, refrigerate immediately

Molecular data

Type: Tripeptide
Chain length: 3 residues
Half-life: 90 min

Dosing reference

Doses reported in the literature and by suppliers. These are a record of what has been used in research — reference, never instruction.

Context	Route	Amount	Frequency
General anti-inflammatory	SubQ	200-300mcg	Once daily
Active inflammation	SubQ	250mcg	Twice daily
Autoimmune support	SubQ	500mcg	Once daily
Acute flare-ups	SubQ	500mcg	2x daily for 1 week, then reduce
Gut health support	Mix in water/juice or enteric capsules	200-500mcg	2-3x daily
Skin inflammation	Affected skin areas	0.1-0.5% cream/gel	2-3x daily
Systemic anti-inflammatory	Nasal spray	100-300mcg	2-3x daily (1-2 sprays per nostril)

Interactions

BPC-157

Enhanced gut healing and anti-inflammatory effects through complementary mechanisms.

synergistic

TB-500

Different mechanisms; can be combined safely.

compatible

LL-37

Complementary antimicrobial and healing effects.

synergistic

Thymosin Alpha-1

Both support immune function through different pathways.

compatible

GHK-Cu

Synergistic for skin health and regeneration.

synergistic

Melanotan II

Both are α-MSH related; KPV lacks pigmentation effects but monitor for cumulative effects.

monitor

Quality checklist

✓High purity >98%
✓Clear, colorless solution after reconstitution
✓Stable small peptide structure
✓Certificate of analysis available
!pH should be 5.5-7 for optimal stability
×Visible particles indicate contamination/degradation
×Yellow coloration indicates oxidation/potency loss

What to expect

Days 1-3Subtle reduction in inflammation, improved energy

Week 1Noticeable decrease in inflammatory symptoms

Week 2-3Improved gut function (if applicable), reduced pain/swelling

Week 4Significant improvement in inflammatory markers

Week 6-8Sustained benefits, improved quality of life

Safety

Commonly reported4

Minimal to no side effects reported
Does not cause immunosuppression like steroids
No melanin production/tanning effects
May temporarily reduce inflammation-related symptoms

Stop and seek advice5

Signs of infection (fever, chills) - very rare
Severe injection site reactions
Paradoxical inflammation increase
Allergic reaction symptoms
Unusual fatigue or weakness

Contraindications3

Known peptide allergies
Active severe infections (theoretical)
Pregnancy or breastfeeding (limited data)

FAQ

Is KPV the same as alpha-MSH or melanotan?

No. KPV is the C-terminal tripeptide fragment of alpha-MSH, not the full hormone. Unlike melanotan, KPV provides anti-inflammatory benefits without causing melanin production or tanning. It's inflammation-focused, not pigmentation-focused.

Can I take KPV orally?

Yes. KPV is one of the few peptides with demonstrated oral bioavailability. It's transported into intestinal cells via PepT1 transporters, making oral capsules or dissolved powder viable alternatives to injection for gut health applications.

How quickly does KPV reduce inflammation?

Effects appear quickly—many users notice reduced inflammation within 1-3 days of starting. By week 1-2, inflammatory symptoms (joint pain, swelling, gut issues) typically show noticeable improvement. Full effects across inflammatory markers appear by week 4-6.

Can I use KPV for autoimmune conditions?

KPV shows promise for autoimmune modulation by reducing pro-inflammatory cytokines (TNF-α, IL-6) without causing immunosuppression. It may help balance overactive immune responses in conditions like Crohn's disease, but requires medical supervision and cannot replace standard treatments.

References

1
Dissection of the Anti-Inflammatory Effect of the Core and C-Terminal (KPV) Alpha-Melanocyte-Stimulating Hormone Peptides
Getting, S.J., Schiöth, H.B., Perretti, M. · Journal of Pharmacology and Experimental Therapeutics · 2003
Established that KPV exerts anti-inflammatory effects distinct from core MSH peptides, likely through inhibition of IL-1β functions rather than melanocortin receptor signaling.
reviewPubMed 12750433 ↗
2
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, et al. · Gastroenterology · 2008
KPV inhibits NF-κB activation and reduces intestinal inflammation via PepT1-mediated transport; demonstrated anti-inflammatory effects in murine IBD models.
reviewPubMed 18061177 ↗
3
Melanocortin-Derived Tripeptide KPV Has Anti-Inflammatory Potential in Murine Models of Inflammatory Bowel Disease
Kannengiesser, K., et al. · Inflammatory Bowel Diseases · 2008
KPV showed significant anti-inflammatory effects in DSS colitis and CD45RBhi transfer colitis models, reducing weight loss, histological damage, and MPO activity. Effects partially independent of MC1R signaling.
reviewPubMed 18092346 ↗
4
Critical Role of PepT1 in Promoting Colitis-Associated Cancer and Therapeutic Benefits of KPV
Viennois, E., et al. · Cellular and Molecular Gastroenterology and Hepatology · 2016
PepT1 is highly expressed in human colorectal tumors. PepT1-transported KPV prevented colitis-associated carcinogenesis in wild-type mice, with no effect in PepT1-knockout mice, confirming PepT1-dependent therapeutic mechanism.
animalPubMed 27458604 ↗
5
Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis
Xiao, B., et al. · Molecular Therapy · 2017
HA-functionalized KPV nanoparticles (~272.3 nm) successfully targeted colonic epithelial cells and macrophages, exerting combined mucosal healing and anti-inflammatory effects superior to free KPV in a UC mouse model.
animalPubMed 28143741 ↗